Kailera Advances Global Ribupatide Obesity Franchise on Strong Oral Phase 2 Data

New updates have been reported about Kailera Therapeutics.

Kailera Therapeutics is accelerating development of its ribupatide obesity franchise following positive Phase 2 data from partner Hengrui Pharma’s once-daily oral formulation in 166 adults with obesity in China, where the drug delivered up to 12.1% mean weight loss at 26 weeks versus 2.3% with placebo and showed no plateau in weight reduction. The safety profile was favorable, with gastrointestinal events largely mild to moderate, vomiting rates at or below 11.4% across active arms, and no permanent discontinuations or dose reductions due to nausea, vomiting, diarrhea, or constipation.

These results de-risk Kailera’s strategy to build a dual injectable–oral ribupatide franchise and support its plan to initiate a global Phase 2 trial of oral ribupatide in 2026, while the KaiNETIC Phase 3 program for once-weekly injectable ribupatide is already under way based on prior data showing 23.6% weight loss at 36 weeks in a Chinese study. Under an exclusive license signed in May 2024, Kailera controls development, manufacturing, and commercialization of Hengrui’s GLP-1 portfolio, including ribupatide, outside Greater China, positioning the company to tap surging global demand for obesity therapies with both a late-stage injectable asset and a potentially differentiated oral option featuring robust efficacy and comparatively low GI-related discontinuation risk.